Contemporary biological insights and clinical management of craniopharyngioma
JR Apps, HL Muller, TC Hankinson, TI Yock… - Endocrine …, 2023 - academic.oup.com
Craniopharyngiomas (CPs) are clinically aggressive tumors because of their invasive
behavior and recalcitrant tendency to recur after therapy. There are 2 types based on their …
behavior and recalcitrant tendency to recur after therapy. There are 2 types based on their …
[HTML][HTML] BRAF–MEK inhibition in newly diagnosed papillary craniopharyngiomas
PK Brastianos, E Twohy, S Geyer… - … England Journal of …, 2023 - Mass Medical Soc
Background Craniopharyngiomas, primary brain tumors of the pituitary–hypothalamic axis,
can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or …
can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or …
[HTML][HTML] Current advances in papillary craniopharyngioma: state-of-the-art therapies and overview of the literature
Craniopharyngiomas are commonly classified as low-grade tumors, although they may
harbor a malignant behavior due to their high rate of recurrence and long-term morbidity …
harbor a malignant behavior due to their high rate of recurrence and long-term morbidity …
Craniopharyngioma—An update on metabolic and cognitive complications and new therapy
EM Erfurth - Journal of Internal Medicine, 2023 - Wiley Online Library
Craniopharyngiomas (CPs) are rare primary brain epithelial tumors arising in the suprasellar
region from remnants of Rathke's pouch. About 50% originate at the level of the third …
region from remnants of Rathke's pouch. About 50% originate at the level of the third …
[HTML][HTML] Case report: Successful use of BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma
ZP Wu, YL Wang, LC Wang, ZY Liu, RR Fan, X Zan… - World Neurosurgery, 2023 - Elsevier
Background As a benign intracranial tumor, craniopharyngioma (CP) treatment has always
been considered a challenging clinical problem. Recently, BRAF V600E mutation in the …
been considered a challenging clinical problem. Recently, BRAF V600E mutation in the …
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
D Reardon, A Cohen, M De La Fuente… - The New England …, 2023 - escholarship.org
BACKGROUND: Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic
axis, can cause clinically significant sequelae. Treatment with the use of surgery, radiation …
axis, can cause clinically significant sequelae. Treatment with the use of surgery, radiation …
Klinička obilježja bolesnika s kraniofaringeomom
B Perić - 2023 - repozitorij.mef.unizg.hr
Sažetak Kraniofaringeom je rijedak, benigni tumor mozga koji ima bimodalnu dobnu
distribuciju, a najčešće se pojavljuje kod djece. Obično se pojavljuje u selarnoj ili …
distribuciju, a najčešće se pojavljuje kod djece. Obično se pojavljuje u selarnoj ili …